Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
25% of today’s total traded volume hit at days end. Single 2,000,000 block.
This stock truly does suck. Owners/Management….come on now!!
Nice!
Lots of large block buys going into the close.
Great entry point!
UPDATE -- Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial
9:31 AM ET 12/3/21 | GlobeNewswire
UPDATE -- Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial
-- Expanding the potential of Bucillamine as an effective treatment for
Omicron variant (B.1.1.529)
-- Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta
variant (B.1.617.2)
-- Adding inflammatory markers along with viral load testing to current
Phase 3 clinical study for COVID-19 aiming to strengthen Bucillamine's
profile as both an anti-viral and anti-inflammatory agent for infectious
diseases
TORONTO, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the Company has decided to expand research with Bucillamine, an oral drug shown to have promising anti-viral and anti-inflammatory capabilities and is being evaluated in a current Phase 3 clinical study for COVID-19, as a potential treatment for the Omicron variant (B.1.1.529).
The expansion to explore Bucillamine's therapeutic potential for the Omicron variant is supported from a recent research study published, titled "Thiol drugs decrease SARS-CoV-2 lung injury in vivo and disrupt SARS-CoV-2 spike complex binding to ACE2 in vitro" from the University of California, San Francisco, which revealed that potent thiol drugs, like Bucillamine, inhibit SARS-CoV-2 infection in vitro, specifically the Delta variant (B.1.617.2) and also reduces SARS-CoV-2-related lung injury in vivo and provides a strong rationale for trials of systemically delivered thiol drugs as COVID-19 treatments. In addition, thiol-based drugs, like Bucillamine, have been shown in research models to decrease the binding of SARS-CoV-2 spike protein to its receptor, decrease the entry efficiency of SARS-CoV-2 spike pseudotyped virus, and inhibit SARS-CoV-2 live virus infection. The Company supported recent research to explore the utility of thiol-based drugs under its sponsored research agreement with the University of California, San Francisco ("UCSF") in the laboratory of Dr. John Fahy. For a copy of the research paper, visit https://www.biorxiv.org/content/10.1101/2020.12.08.415505v2.full.pdf
In a study that evaluated the role of pro-inflammatory cytokines that are highly upregulated in patients with COVID-19 in inducing inflammatory cell death, inflammation, tissue and organ damage, and mortality showed that the specific combination of tumor necrosis factor (TNF-) and interferon (IFN-) is critical for these processes. Furthermore, it was found that inhibiting TNF- and IFN- protected against death in SARS-CoV-2 infection and models of sepsis, hemophagocytic lymphohistiocytosis (HLH), and cytokine shock, suggesting that this pathway can be applicable beyond COVID-19 in infectious and inflammatory diseases where TNF- and IFN--mediated inflammatory cell death drive the pathology (Karki, Rajendra et al. 2020).
There is evidence that Bucillamine inhibits pro-inflammatory cytokine production and transendothelial T-cell migration, both of which could further dampen disease course in COVID-19 (Horowitz LD. 2003, Munakata Y. 2000). As a result of the research and the rise of the Delta variant and Omicron variant, the Company has decided that in addition to incorporating viral load testing, which it announced on November 16, 2021, it will also be adding inflammatory markers to complement the ongoing Phase 3 clinical trial (ClinicalTrials.gov Identifier: NCT04504734) evaluating the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19. These inflammatory markers will allow the Company to understand Bucillamine's potential as an anti-inflammatory agent in the treatment course and provide confidence in the potential utility and effectiveness of Bucillamine in COVID-19.
Michael Frank, CEO of the Company, commented, "Bucillamine has thus far shown in published research to be agnostic as a potential treatment to certain COVID-19 variants, including the Delta variant, and with the rise of the Omicron variant, we are motivated in expanding research with Bucillamine to explore its therapeutic utility for the Omicron variant. In addition, we are incorporating inflammatory markers to complement the viral load testing to our remaining patients in our ongoing Phase 3 study to support Bucillamine as a safe and effective anti-inflammatory and anti-viral oral agent for mild to moderate COVID-19."
The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time.
Where is everyone?
Nice close.
Appears to be solid retail buying this morning!
Mandate should be overturned by SC
Nothing but sells on the trading block.
Sello do you see any light at the end of the tunnel….this black hole?
Gig Em!
Anyone ready for the next leg up?
Would be nice!
This stock sure is sucking wind!
Good morning to all! In need of some positivity it’s morning. How will the good news for an NRX translate over to Relief?
When?
Which company does AI robot Janet belong to? She’s made Denny’s news
So very true
Same.
Ditto!
My bad 1A
Can anyone provide legitimate insight as to what A1 means moving forward?
Tia
3
Lol…yup!
Same….you too Stay safe!!
Add another 0 in front of the 3
Thanks you too! Spent with family and friends. Such an enjoyable and peaceful day!
Will we see upward movement in RLFTF?
Happy Thanksgiving!!
May I dare ask....who's the 1.3mm at .003 trying to buy?
Thanks!
Nice action today. Almost 2:1 buys versus sell
Good information Sello....Thank you. So in your best opinion, what are the "powers that be" doing letting this SP drop so far down in to the bucket of sub penny. What is the advantage? What is the reason. These prices are nice so as to accumulate huge share holdings for flipping on small moves but does nothing to legitimize the company. I'm a large holder with the intention to invest in solid, undiscovered novel concept companies. I intend to hold through 2022 with the hopes that something solid can come out of all this.
Good luck to all!
3BB
Any reality to the ability of ipix to move back up to .20’s and .30’s without RS?
I doubt one could even then….mandating something one can not self evaluate is just wrong….imho.
That is absurd!
Ditto…me too.
RLFTF or converting to ADRs?
I imagine powers will keep the .06 SP at depressed level
I’m weighing the risk. .06 (bottom) versus $15 to $10 to $9…..so forth and so on.